Publication|Articles|November 18, 2026

Supplements

  • Practical Considerations for Stroke Prevention Across the Continuum

A Quick-Reference Guide for Multidisciplinary Stroke Prevention Rounds

Fact checked by: Ron Panarotti
Listen
0:00 / 0:00

Key Takeaways

  • FXIa inhibition targets thrombus propagation with limited impact on hemostasis, supporting stroke prevention without a proportional bleeding penalty versus traditional anticoagulant pathways.
  • OCEANIC-STROKE randomized 12,327 patients within 72 hours to asundexian 50 mg daily plus SAPT/DAPT, reducing ischemic stroke (HR 0.74) and CV death/MI/stroke (HR 0.83).
SHOW MORE

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

This content was independently produced by Pharmacy Times in partnership with Bayer HealthCare.

Approximately 5.1% of patients with an ischemic stroke or transient ischemic attack (TIA) have a recurrent stroke within 1 year.1 Closing that gap depends on getting the antithrombotic regimen, its duration, and the surrounding risk-factor plan right before the patient leaves the hospital.

Health-system pharmacists are well positioned to do that work on multidisciplinary rounds. They confirm that therapy matches the stroke mechanism, screen for bleeding risk and drug interactions, and make sure stop dates and follow-up plans survive the transition to outpatient care.

That role is about to expand. Asundexian (Sunharbo; Bayer HealthCare), an investigational oral factor XIa (FXIa) inhibitor, was approved by the FDA for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk TIA.2 It is the first agent in a new antithrombotic class for this population, and pharmacists will be central to identifying which patients fit the evidence. The checklist below is designed to help pharmacists prepare for rounds and ask the right questions of each patient on stroke-prevention therapy.

The Evidence: FXIa Inhibition and OCEANIC-STROKE

FXIa contributes to pathologic thrombus growth but appears to play a smaller role in normal hemostasis, which is the rationale for targeting it to prevent stroke without a proportional increase in bleeding. The phase 3, double-blind OCEANIC-STROKE trial (NCT05686070) randomly assigned 12,327 patients within 72 hours of a noncardioembolic ischemic stroke or high-risk TIA to asundexian 50 mg once daily (n = 6162) or placebo (n = 6165), each added to planned single- or dual-antiplatelet therapy.1 Eligible patients had at least 1 of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or atherosclerotic plaque on cerebrovascular imaging. Median follow-up was about 19 months.3

In patients treated with asundexian, ischemic stroke was less common (6.2%) than in those receiving placebo (8.4%; HR, 0.74; 95% CI, 0.65-0.84; P < .001). Additionally, cardiovascular death, myocardial infarction, or stroke occurred in 9.2% and 11.1% of patients in these respective groups (HR, 0.83; 95% CI, 0.74-0.92; P < .001). The incidence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding and major or clinically relevant nonmajor bleeding was similar in patients treated with asundexian and in those receiving placebo (ISTH major bleeding: 1.9% vs 1.7% [HR, 1.10; 95% CI, 0.85-1.44; P = .46]; major/clinically relevant nonmajor bleeding: 5.5% vs 5.0% [HR, 1.12; 95% CI, 0.96-1.30; P = .16]).1,3

Asundexian’s benefit in reducing stroke was consistent across age, sex, stroke subtype (including small-vessel occlusion), and stroke severity, and the trial included patients with a National Institutes of Health Stroke Scale (NIHSS) score up to 15 and those who received thrombolysis or thrombectomy.1

The FDA accepted Bayer’s new drug application with priority review in May 2026 and received approval in November 2026.2

The Rounds Checklist

Confirm the Stroke Mechanism.

  • Is the event classified as noncardioembolic
    (large-artery atherosclerosis, small-vessel disease,
    or other/undetermined)?
  • For cryptogenic stroke, has prolonged cardiac rhythm
    monitoring been ordered to exclude atrial fibrillation (AF)?5
  • If AF is identified, is the patient transitioning to oral anticoagulation rather than antiplatelet or FXIa-based therapy?4,5
  • Are the NIHSS score (stroke) or ABCD2 score (TIA) and time from symptom onset documented? These drive regimen eligibility.

Match the Antiplatelet Regimen and Duration to the Evidence.

  • Minor stroke (NIHSS ≤3) or high-risk TIA (ABCD2 ≥4): aspirin plus clopidogrel started within 24 hours and continued for 21 to 90 days, then single antiplatelet therapy.4
  • Ticagrelor plus aspirin for 30 days is an alternative for NIHSS score of 5 or lower or high-risk TIA.6
  • Is the CYP2C19 genotype known? Ticagrelor plus aspirin outperformed clopidogrel plus aspirin in CYP2C19 loss-of-function carriers.7
  • Is a dual antiplatelet therapy stop date written in the chart and discharge summary?

Assess Candidacy for Asundexian.

  • Does the patient resemble the OCEANIC-STROKE population: within 72 hours of a noncardioembolic ischemic stroke or high-risk TIA, with a nonlacunar infarct, known atherosclerosis, or plaque on imaging?3
  • Is asundexian being added to (not substituted for) antiplatelet therapy? The studied dose was 50 mg once daily.1
  • Now that it is FDA-approved, review the prescribing information for renal and hepatic dosing, drug interactions, and perioperative management.

Screen for Bleeding Risk.

  • Review imaging for hemorrhagic transformation, plus any history of intracranial hemorrhage, recent major bleeding, or gastrointestinal (GI) bleeding.
  • Check platelet count, hemoglobin, and fall risk.
  • Add a proton pump inhibitor for patients on dual antiplatelet therapy with GI risk factors; pantoprazole avoids the CYP2C19 interaction seen with omeprazole and esomeprazole.
  • Remove duplicate antithrombotics (eg, home aspirin continued alongside a new regimen) and unnecessary nonsteroidal anti-inflammatory drugs.

Reconcile Medications and Interactions.

  • Screen home medications and supplements (eg, fish oil, ginkgo) that add bleeding risk.
  • For ticagrelor, confirm the aspirin maintenance dose is no more than 100 mg daily and avoid strong CYP3A4 inhibitors and inducers.
  • Flag selective serotonin reuptake inhibitors started for poststroke depression as an added bleeding consideration.

Address Vascular Risk Factors.

  • High-intensity statin therapy, with ezetimibe as needed, to reduce low-density lipoprotein cholesterol to below 70 mg/dL in patients with atherosclerotic disease.4
  • Blood pressure goal is below 130/80 mm Hg for most patients.4
  • Diabetes management and smoking cessation pharmacotherapy are addressed before discharge.

Secure the Transition of Care.

  • Is prior authorization or formulary review needed for the discharge regimen?
  • Has the patient been counseled on each antithrombotic, its duration, and bleeding warning signs?
  • Are the stop dates, monitoring plan, and neurology follow-up communicated to the primary care team?

Quick Reference: Asundexian at a Glance1

  • Class: oral FXIa inhibitor
  • Regulatory status: approved by the FDA2
  • Studied population: within 72 hours of noncardioembolic ischemic stroke or high-risk TIA3
  • Studied dose: 50 mg once daily, added to single or dual antiplatelet therapy
  • Ischemic stroke: 6.2% vs 8.4% with placebo (26% relative reduction)
  • ISTH major bleeding: 1.9% vs 1.7% with placebo
  • Median follow-up: 19 months

Bringing It to Rounds

Most of this checklist applies today: confirming the stroke mechanism, timing dual antiplatelet therapy correctly, and closing gaps in bleeding and risk-factor management. The asundexian questions prepare pharmacists for a decision that may soon reach the formulary committee and the bedside. By arriving with these questions answered, pharmacists help the team match each patient to the strongest available evidence and carry that plan safely past discharge.

REFERENCES
  1. Sharma M, Dong Q, Hirano T, et al; OCEANIC-STROKE Investigators. Asundexian for secondary stroke prevention. N Engl J Med. 2026;394(15):1467-1479. doi:10.1056/NEJMoa2513880
  2. FDA approves first factor Xla inhibitor to help prevent stroke in certain adults at high risk. News release. FDA. November 9, 2026. Accessed November 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
  3. Ciccone I. Newly published phase 3 OCEANIC-STROKE trial data show asundexian reduces recurrent ischemic stroke risk. NeurologyLive. April 16, 2026. Updated April 17, 2026. Accessed October 8, 2026. https://www.neurologylive.com/view/newly-published-phase-3-oceanic-stroke-trial-data-show-asundexian-reduces-recurrent-ischemic-stroke-risk
  4. FDA approves first factor Xla inhibitor to help prevent stroke in certain adults at high risk. News release. FDA. November 9, 2026. Accessed November 10, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-factor-xla-inhibitor-help-prevent-stroke-certain-adults-high-risk
  5. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375
  6. Piccini JP, Patel MR, Steffel J, et al; OCEANIC-AF Steering Committee and Investigators. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med. 2025;392(1):23-32. doi:10.1056/NEJMoa2407105
  7. Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207-217. doi:10.1056/NEJMoa1916870
  8. Wang Y, Meng X, Wang A, et al; CHANCE-2 Investigators. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. N Engl J Med. 2021;385(27):2520-2530. doi:10.1056/NEJMoa2111749

Related to this article